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Non.Small! Cell! Lung! Cancer! (NSCLC)! is! a! highly! resistant! cancer! with! only! ~30%! of! tumours!
responding! to! first.line! cisplatin! chemotherapy! following! surgery.! To! improve! treatment!
outcomes,!preclinical!models!are!urgently!required!that!better!predict!individual!patient!response!
to!novel!therapies.!Using!freshly!resected!tumour!tissue,!we!have!established!an!optimal!ex#vivo!




















receive! palliative! chemotherapy! alone.!Most! patients! receive! combination! chemotherapy!based!
on!clinical!parameters!of!cisplatin!or!carboplatin!with!at!least!one!other!drug!such!as!Vinorelbine,!




some! of! which! rely! on! pre.selection! of! cancers! according! to! genetic! mutation.! For! example,!
selective! EGFR! inhibitors! gefitinib! and! erlotinib! provide! clinical! benefit! over! standard!
chemotherapy!for!NSCLC!tumours!bearing!EGFR!mutations!(2,3)!while!the!ALK!inhibitor!crizotinib!
benefits! ALK.mutated! cases! (4).! A! global! industry! is! centred! on! assessing! additional! mono.! or!
combinatorial!treatments!in!NSCLC!clinical!trials.!Despite!this!momentum,!late.stage!failures!are!a!
reality! and! there! is! <11%! success! in! bringing! a! drug! to!market! (5),! attributable! in! part! to! non.
predictive!preclinical!drug!platforms! (6,7).! The! incorporation!of!Patient.Derived!Xenograft! (PDX)!
mouse!models! (8,9)! into!preclinical!studies!has! improved!predictive!accuracy!somewhat! (10,11).!
However,!PDX!efficacy!studies!are!expensive,!requiring!large!numbers!of!mice.!Furthermore,!not!
all! primary! human! tumours! generate! PDXs! and,! of! those! that! do,! serial! propagation! can! select!
tumours!that!adapt!to!grow!in!an!immunocompromised!environment.!
!
An! alternative! approach! is! to! use! three.dimensional! ex#vivo! culture! of! fresh! human! tumours.!
Methods!for!ex#vivo!culture!of!human!tumours!have!been!available!for!many!years!and!evidence!
shows!that!they!can!reliably!reflect!tumour!growth!in+vivo!(12.17).!Here,!we!have!developed!and!
perfected! an! ex#vivo! culture! method! for! NSCLC! tumour! samples! that! is! both! simple! and!
reproducible.! We! have! optimized! culture! conditions! and! show! that! tumour! and! stroma! are!
retained! and! viable.! As! proof! of! concept,! NSCLC! explant! response! to! the! standard.of.care!
chemotherapy!drug!cisplatin!was!examined!as!well!as!response!to!the!targeted!agent!TRAIL.!We!








Fresh! NSCLC! tumours!were! collected! from! consented! patients! undergoing! lung! surgery! (Ethical!
approval:!LREC:!07/MRE08/07).!Patients!had!no!prior!exposure!to!chemotherapy.!Viable!tumour!
areas! were! identified! by! frozen! tissue! sectioning! and! Haematoxylin! and! Eosin! (H&E)! staining.!
Tissue!was!placed!in!Hank’s!Balanced!Salt!Solution!and!cut! into!fragments!of!2.3!mm³!using!two!
skin!graft!blades!on!a!dental!wax!surface.!These!were!placed!in!fresh!culture!media!(DMEM!with!
4.5! g/L!Glucose! plus! 0.5%! FCS! and! 1%!pen/strep);! nine! fragments!were! randomly! selected! and!
placed! on! a! 0.4! µm! culture! insert! disc! (Millipore)! floated! on! 1.5!ml! of!media! in! a! 6.well! dish.!
Explants!were!incubated!at!37°C!and!5%!CO2!for!16.20!hours.!Discs!were!then!transferred!to!new!
wells! containing! 1.5!ml! fresh!media! and! drugs! or! carrier! control!were! added! to! each!well! in! a!












Clone!MIB.1:! DAKO! 1:2000,! p53!DO1:! gift! from!David! Lane! 1:1000,! Cytokeratin! clone!MNF116:!
DAKO! 1:5000.! Antibodies! were! diluted! in! blocking! solution!made! with! 3%! (w/v)! Bovine! Serum!

















Significance! of! proliferation/death! indices!was! determined! by!Wilcoxon!matched! pairs! test! and!
Jonckheere.Terpstra!trend!test,!respectively.!Unpaired!data!were!compared!by!the!Mann.Whitney!
U! test!or!Kruskal.Wallis!one.way!ANOVA.!Paired!data!were!analyzed!by! the!Page!L! test! (Unistat!















distribution! of! NSCLC! cases! in! the! UK! (24).! A! proportion! of! NSCLC! tumours! are! known! to! be!
necrotic! (25)! and!an! important! first! step!was! to!exclude! such! tumours! from!analysis!using!H&E!
assessment.!This!led!to!the!identification!of!13!tumours!(~32%)!that!were!excluded!from!explant!
generation.! Supplementary! Fig.! S2! indicates! the! histological! type! (Supplementary! Fig.! S2A)! and!
stage!(Supplementary!Fig.!S2B)!of!viable!and!non.viable!tumours.!The!highest!proportion!of!non.






(Fig.! 1A,! B).! SCC! tumours! displayed! significantly! higher! levels! of! proliferation! than! ADC,! while!
Atypical! Carcinoid! (AC)! tumours! were! essentially! indolent! (Fig.! 1A).! These! observations! are!








Explants! were! routinely! allowed! to! recover! for! a! period! of! 16.20! hours! after! their! initial!
generation;! viability! was! assessed! over! a! time! range! of! 24.72! hours! after! recovery! for! five!
tumours.!As!shown!in!Fig.!2A,!a!trend!of!decreasing!cell!proliferation!and!increasing!cell!death!with!
increasing! time! of! culture!was! observed! suggesting! ex#vivo! explant! cultures! are!more! viable! in!
short!term!culture.!Varying!FCS!concentration,!from!0.5%,!at!24!hours!of!culture!after!the! initial!




concentration! is!not! a! significant! factor.! Subsequent!analyses!of!drug! responses!were! therefore!
performed!for!24!hours,!using!1%!as!the!standard!FCS!concentration.!Pooled!data!for!21!explants!
under! these! conditions! are! shown! in! Fig.! 2C.! Overall,! there! is! a! small! but! significant! effect! of!






cell! proliferation! were! only! marginally! affected! by! the! drug! (Supplementary! Fig.! S3B)! and!
therefore! the!emphasis!was!placed!on!assessing! cell! death! responses! (Supplementary!Fig.! S3A).!
Cell!death!response!for!each!tumour!was!calculated!as!fold.induction!relevant!to!the!control!over!






a! single!dose!of! 50!µM!cisplatin.!We!obtained! clinical! and!histopathology! information!on!all! 26!
patients!and!their!tumours!(Supplementary!Table!S1).!Cell!death!difference!compared!to!control!in!






We! then! categorized! each! explant! into! being! either! sensitive! or! resistant! to! cisplatin!
(Supplementary!Fig.!S4B!and!Table!S1).!Using!clinical!information!on!corresponding!patients!(Table!
S1),! the! relationship!of!cisplatin! sensitivity/resistance! in!explant!culture! to!patient! survival!post.
surgery!was!determined! (Fig.!3B).!The!data! show!a!statistically! significant! relationship! (P=0.019)!
with!sensitive!cases!demonstrating!a!Mean!Survival!Time!(MST)!of!44!months!and!resistant!cases!a!
MST! of! 26!months.! Cisplatin! sensitivity! in! explants! was! also! correlated! with! tumour! stage! and!
! 8!
histological! type! (Fig.!3C).!There!was!a! significant!negative! trend!between!difference! in!%cPARP!
staining!compared!to!control!in!response!to!cisplatin!and!increasing!tumour!stage!suggesting!more!
advanced! tumours! are! more! resistant! to! the! drug.! There! was! also! a! significant! correlation!
between! cisplatin! sensitivity! and! tumour! type! with! SCC! cases! demonstrating! greater! cisplatin!




A! number! of! mechanisms! have! been! reported! to! render! cells! resistant! to! cisplatin! including!
reduced! drug! uptake,! enhanced! export,! drug! deactivation,! increased! repair! of! DNA! damage! or!









The!TP53! gene! is! frequently!mutated! in!NSCLC! (31).!Wild.type! TP53!protein! is! induced!by!DNA!
damaging! agents! such! as! cisplatin,! whereas! mutated! TP53! is! either! not! expressed! or! is!
constitutively!expressed.!We!utilized!immunohistochemistry!to!gain!an!indication!of!TP53!function!
in! the! 26! tumours,! identifying! three! categories:! a)! WTTP53! tumours! (10! tumours),! b)! MUTTP53!
tumours! with! constitutively! high! TP53! levels! (14! tumours),! c)! MUTTP53! tumours! expressing!
undetectable! TP53! (2! tumours).! Immunohistochemical! TP53! staining! of! positive! and! negative!
















been! disappointing! (33).! It! is! thought! that! preclinical! in+ vitro! studies! using! cell! lines! have! not!
faithfully! represented! the! clinical! situation.! This! is! supported! by! data! demonstrating! that! the!
majority! of! primary! human! tumour! cells! are! resistant! to! TRAIL! receptor! agonist! (33.35).! To!
investigate!TRAIL!sensitivity!in!NSCLC,!12!explants!were!treated!with!TRAIL!either!as!a!single!agent!
or!in!combination!with!cisplatin!(Fig.!6A).!TRAIL!alone!did!not!elicit!a!strong!response,!except!for!












the! characteristics! of! the! original! human! tumour! microenvironment! over! time.! Here,! we! have!
perfected!a! rapid!and! low!cost!platform!that! relies!on! the! in+ situ! assessment!of!drug! responses!
within! real!human! tumours.!We!validate! this!platform!by! showing! that!explant! response! to! the!
standard.of.care! chemotherapy!drug! cisplatin! is! related! to! survival! of!patients!who!also! receive!
this!drug!after!surgery!(P=0.019).!Responses!to!the!targeted!agent!TRAIL!are!also!more!consistent!




17).! In!most!of! these!previous! systems,!viability!of! tumours!has!been!demonstrated! for!up! to!7!
days!(12.17).!Here,!we!identified!a!mild!effect!of!cultivation!after!24!hours!of!culture!(Fig.!2C),!but!











than!WTTP53! cases! (Fig.! 5D).! Previous! studies! have! investigated!whether!TP53+mutations! are! of!
prognostic!value! in!predicting! response! to!chemotherapy! in!NSCLC;! the!results!are!controversial!




Another! report! in! the! International! Adjuvant! Lung! Cancer! Trial! (IALT),! a! randomized! trial! of!
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Figure' 1.' Intrinsic( levels% of% proliferation% and% apoptosis% in# the$ tumours' used' for' explants.! A,!
Proliferation+was+ assessed+by+quantitating+Ki67+ immunohistochemical+ staining+ and+ cell+ death+by+
quantitating(cPARP(staining.(The$left$panel$indicates$the$%"of#intrinsic'proliferation'and'cell'death'








Immunohistochemical& stains& were& counterstained) with) haematoxylin.) LT103) (high$ proliferative+
tumour)! and$ LT98$ (medium$ proliferative$ tumour)$ represent' SCC! samples' whereas' LT104" (low"
proliferative+tumour)+is!an#ADC.%Scale%bars%=%100%µm.#!
Figure' 2.' Establishment,of, optimal, explant, culture, conditions.!A,!Evaluation*of* proliferation* and*
cell$ death$ levels$with$ increasing$ time$ of$ explant$ culture.$ The$%!Ki67% (left% graphs)% and%%! cPARP$
(right'graphs)' immunohistochemical+staining+of+five!NSCLC!ex#vivo!explants!over%time%are%shown."
The$ staining$ values$ were$ generated$ from$ the$ uncultured$ tumour$ in$ its$ native$ state! and$ from$
explants)from%the%same%tumour%at#24,!48#and#72#hours#of#culture#after#an#initial#recovery#of#16.20#
hours.'The$graphs$at$the$top"show"individual"values"for"each"of"the"five"tumours."The"graphs"on"
the$bottom$ indicate$pooled$mean$ values$ for$ the$ five$ samples$±!95%$CI.$Page's' L' nonparametric'
trend& test& showed& a& negative& trend& for$ Ki67$ staining$with% increasing% culture% time% (P! =! 0.01;% L!
statistic& =!143)% and%a"positive" trend! for$ cPARP$ staining!with% increasing% culture% time% (P!=!0.05;" L"
statistic!=!140).!B,!Evaluation*of*%!Ki67%and%%!cPARP$staining$with%varying(FCS$concentrations.$The$
%!Ki67% (left% graphs)%and%%!cPARP$ (right$graphs)$ immunohistochemical+ staining+of+ five!NSCLC%ex#
vivo! explants! over% time% are% shown." The" staining" values" were$ generated$ from$ the$ uncultured$
tumour& in& its& native& state! and$ from$ explants$ from$ the$ same$ tumour! cultured( in( varying( FCS(
concentrations* for*24*hours*after*an* initial& recovery&of&16.20#hours.!The$graphs$at$ the$ top$show$
individual( values( for(each(of( the( five( tumours.( The(graphs(on( the(bottom( indicate(pooled(mean(








Figure' 3.'NSCLC%explant% response! to#cisplatin.!A,!Fold%Cell!Death&relative& to&control&of&17#NSCLC%
explant( cultures( treated(with(a"dose" range" (0.50#µM)!of# cisplatin.#The#%#cPARP%staining%of#each#
sample'was!quantitated)within&explants)from)the)same)tumour)cultured)in)carrier&control&(DMF)&or&
increasing)cisplatin)concentrations)(1)µM,)10)µM)and)50)µM))for)24)hours)after)an)initial)recovery)
of#16.20#hours.#The#value# for#each#treatment#was#divided#by# the#carrier#control# to#obtain'a" fold"
change.!B,!Kaplan.Meier%patient% survival% correlated%with% sensitivity%of%explants% to%cisplatin%at%50%
µM.!Data$was$evaluated$for$25#patients/explants#(Table#S1).#The$threshold"of"sensitivity/resistance"








between& increasing) stage) and) cisplatin) response.)Correlation*of# tumour# histology#with# cisplatin#
response' demonstrated' statistically' significant$ differences$ between$ SCC$ samples$ and$ both$ ADC$
and$AC$types.!
!
Figure' 4.' Pt# ion$ distribution$ in" cisplatin( sensitive( and( resistant! explants.! A,! Cisplatin) resistant(
explant( (LT31)!and! (B)$cisplatin) sensitive!explant( (LT88)." Both! samples'were$ treated&with&10"µM"
cisplatin.*Serial'sections'of'explants'stained'with'H&E$staining$are$shown$in$the$top$left$panels,$and$
immunohistochemical-staining-with-antibodies-for-MNF116& (top%middle%panels),%cPARP%(top%right!





Figure' 5." TP53# expression.! A,! Immunohistochemical. staining. of. explants. treated& with& cisplatin&
demonstrating,tumours'with'constitutively,high,levels%of%nuclear%TP53#in#tumour#cells!(LT18,'LT27'
and$LT23)$or#low#levels#of#TP53!(LT116).!Scale&bars&=&100#µm.!B,!Immunohistochemical.staining.and.
quantitation(of(nuclear(p53( staining( in( a( TP53WT!explant( sample!demonstrating,dose.dependent&
TP53! expression) following) cisplatin) treatment.) The$ graph$ shows$ the$%"mean" labelling" index" of"
TP53# ±! SD# following# treatment# of! the$ tumour$ sample$ with! increasing) doses) of) cisplatin) (P! <"
0.0001).% Scale& bars& =& 100& µm.# C,! Correlation* of* intrinsic* proliferation* index* with* TP53*
immunohistochemical- staining.- The$ graph$ shows$ the$ %! Ki67" staining" of" tumours& classified&
according)to)TP53#immunohistochemical-staining."Each"circle"represents"one"sample."D,!Induction)








twelve! ex#vivo! explant( cultures% as% determined% by% cPARP$ staining$ was$ determined$ after& each%
treatment'for'24'hours'after'an'initial'recovery'of'16.20#hours."These"values!were$divided$by$the$












































































































































Cisplatin dose (µM) 


















Carrier control 1 µM cisplatin 
50 µM cisplatin 10 µM cisplatin 
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TRAIL 1µg/ml + 50µM Cisplatin 
A 
Figure 6 
Carrier 1µg/µl TRAIL 50µM Cisplatin TRAIL + Cisplatin 
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